DigestRedComo funciona
Red
/
Empresas
Ka
No verificado

KaliVir Immunotherapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
19/11/2025
Mercado laboral
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0
01/10/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0
20/05/2025
Industria
Ciencia
Biotecnología
Oncología
Salud
Higiene alimentaria
Medicina - Varios
KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0
25/03/2025
Eventos
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0
18/11/2024
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Industria
KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0
08/10/2024
Industria
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0
04/09/2024
Biotecnología
Farmacéutica
Salud
Oncología
Mercado laboral
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0
01/07/2024
Industria
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors
Fuente
KaliVir Immunotherapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0